Who
R. Kent McGaughy Jr.
Director
Company insider
Files Form 4 as: Director, Instil Bio; Director and 10% owner, Reata Pharmaceuticals; Director and 10% owner, Apollo Endosurgery; 10% owner, PROCEPT BioRobotics; Director, Genitope.
In numbers
- Trades disclosed
- 153
- Buys
- 32
- Sells
- 0
- Bought
- $76.8M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 11 Jun 2007
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 28 May 2025filed 29 May 2025 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,692,857 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —51,095 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —3,109 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —278,309 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —6,300 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —699 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —690 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —399 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,240 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —4,787 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,628 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —4,275 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —2,773 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —6,000 | filing |
News
No headline names them, or the companies they trade most, lately.